Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). It is also used as an appropriate treatment of chronic myelomonocytic leukemia (CMML) in the real life setting. As treat...

Descripció completa

Dades bibliogràfiques

Autors principals:	Nikolova D., Yordanov A., Radinov A.
Format:	Artigo
Idioma:	Inglês
Publicat:	Sciendo 2021-10-01
Col·lecció:	Acta Medica Bulgarica
Matèries:	azacitidine (aza, vidaza®) monitoring blood count parameters toxicity cytogenetic findings
Accés en línia:	https://doi.org/10.2478/amb-2021-0030
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!